Abstract:Many neurodegenerative diseases are characterized by accumulation of toxic protein aggregates in specific subcellular locations. Using mouse models, Peng et al. show that inhibition of the endoplasmic reticulum acetylation machinery enhances autophagy-mediated disposal of aggregates that form within the secretory pathway and rescues Alzheimer's disease.See Duran-Aniotz et al. (doi 10.1093/brain/awv401) for a scientific commentary on this article.Many neurodegenerative diseases are characterized by accumulation of toxic protein aggregates in specific subcellular locations. Using mouse models, Peng et al. show that inhibition of the endoplasmic reticulum acetylation machinery enhances autophagy-mediated disposal of aggregates that form within the secretory pathway and rescues Alzheimer's disease.The aberrant accumulation of toxic protein aggregates is a key feature of many neurodegenerative diseases, including Huntington's disease, amyotrophic lateral sclerosis and Alzheimer's disease. As such, improving normal proteostatic mechanisms is an active target for biomedical research. Although they share common pathological features, protein aggregates form in different subcellular locations. N epsilon-lysine acetylation in the lumen of the endoplasmic reticulum has recently emerged as a new mechanism to regulate the induction of autophagy. The endoplasmic reticulum acetylation machinery includes AT-1/SLC33A1, a membrane transporter that translocates acetyl-CoA from the cytosol into the endoplasmic reticulum lumen, and ATase1 and ATase2, two acetyltransferases that acetylate endoplasmic reticulum cargo proteins. Here, we used a mutant form of alpha-synuclein to show that inhibition of the endoplasmic reticulum acetylation machinery specifically improves autophagy-mediated disposal of toxic protein aggregates that form within the secretory pathway, but not those that form in the cytosol. Consequently, haploinsufficiency of AT-1/SLC33A1 in the mouse rescued Alzheimer's disease, but not Huntington's disease or amyotrophic lateral sclerosis. In fact, intracellular toxic protein aggregates in Alzheimer's disease form within the secretory pathway while in Huntington's disease and amyotrophic lateral sclerosis they form in different cellular compartments. Furthermore, biochemical inhibition of ATase1 and ATase2 was also able to rescue the Alzheimer's disease phenotype in a mouse model of the disease. Specifically, we observed reduced levels of soluble amyloid-beta aggregates, reduced amyloid-beta pathology, reduced phosphorylation of tau, improved synaptic plasticity, and increased lifespan of the animals. In conclusion, our results indicate that N epsilon-lysine acetylation in the endoplasmic reticulum lumen regulates normal proteostasis of the secretory pathway; they also support therapies targeting endoplasmic reticulum acetyltransferases, ATase1 and ATase2, for a subset of chronic degenerative diseases.

Improved Proteostasis in the Secretory Pathway Rescues Alzheimer’s Disease in the Mouse

Nϵ-lysine Acetylation in the Lumen of the Endoplasmic Reticulum: A Way to Regulate Autophagy and Maintain Protein Homeostasis in the Secretory Pathway

Enhancement of Lysosome Biogenesis As a Potential Therapeutic Approach for Neurodegenerative Diseases.

ATase Inhibition Rescues Age-Associated Proteotoxicity of the Secretory Pathway.

Proteins in Aggregates Functionally Impact Multiple Neurodegenerative Disease Models by Forming Proteasome-Blocking Complexes

Stabilizing the Retromer Complex in a Human Stem Cell Model of Alzheimer’s Disease Reduces TAU Phosphorylation Independently of Amyloid Precursor Protein

Inhibition of the Dopamine Transporter Promotes Lysosome Biogenesis and Ameliorates Alzheimer's Disease–like Symptoms in Mice

Effects of Lanthionine Ketimine-5-Ethyl Ester on the α-Synucleinopathy Mouse Model

Enhancing Mitochondrial Proteostasis Reduces Amyloid-Β Proteotoxicity.

Acetylation of AMPA Receptors Regulates Receptor Trafficking and Rescues Memory Deficits in Alzheimer's Disease

Reprogramming the neuronal secretory and metabolic machinery using correctors for Alzheimer therapy

TFEB acetylation promotes lysosome biogenesis and ameliorates Alzheimer’s disease–relevant phenotypes in mice

P2-296: Enhanced Proteolysis of Aβ Peptide Reduces Tau Phosphorylation and Neurofibrillary Tangle Formation in APP/tau Transgenic Mice

Antagonists Targeting Eef2 Kinase Rescue Multiple Aspects of Pathophysiology in Alzheimer's Disease Model Mice

Genetic Reduction of Eef2 Kinase Alleviates Pathophysiology in Alzheimer’s Disease Model Mice

Spatial Selectivity of ATase Inhibition in Mouse Models of Charcot-Marie-Tooth Disease

Enhancing Retromer Complex Stability Ameliorates Synaptic Dysfunction in a Mouse Model of Alzheimer's Disease

α-synuclein buildup is alleviated via ESCRT-dependent endosomal degradation brought about by p38MAPK inhibition in cells expressing p25α

Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing

The role of altered protein acetylation in neurodegenerative disease

ACSS2-dependent Histone Acetylation Improves Cognition in Mouse Model of Alzheimer's Disease.